{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:45:11Z","timestamp":1789083911623,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Idecabtagene vicleucel (ide-cel) induces deep responses in relapsed\/refractory multiple myeloma, yet more than half of patients relapse within 1 year. The intrinsic features of chimeric antigen receptor T-cell (CAR-T) products that distinguish durable from nondurable responders are poorly defined, particularly at single-cell resolution, and defining drivers of durable response is critical to guide patient counseling and to inform strategies for optimizing CAR-T manufacturing and efficacy. To address this need, 40 ide-cel infusion products (184\u2009398 cells) were profiled using single-cell RNA sequencing. These analyses revealed that a transcriptional program in CD4 CAR-T cells that led to durable responses is characterized by NF-\u03baB signaling, prosurvival circuits, tonic\/chemokine signaling, and elevated CAR transgene expression. These features were associated with prolonged progression-free and overall survival irrespective of baseline clinical characteristics. Further, analyses of paired apheresis and tumor microenvironment samples showed that elevated NF-\u03baB activity is an intrinsic hallmark of T-cell fitness that is characterized by a central memory phenotype and the lack of checkpoint receptor expression, and that these features were manifest in marrow-derived and peripheral blood T cells before CAR-T manufacturing. Finally, validating functional relevance, the pharmacologic inhibition of NF-\u03baB abrogated CAR-T cytotoxicity and cytokine production in vitro. Our results support that NF-\u03baB in the ide-cel product marks a signaling axis affecting CAR-T function and that NF-\u03baB activity represents a global marker of T-cell fitness present before CAR-T manufacture.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031843","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:53:01Z","timestamp":1781196781000},"page":"1409-1422","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Product-intrinsic NF-\u03baB\u2013driven transcriptional programs connote durability of CAR-T response in multiple myeloma"],"prefix":"10.1182","volume":"148","author":[{"given":"Jerald D.","family":"Noble","sequence":"first","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-0194","authenticated-orcid":false,"given":"Barbara C.","family":"Peixoto","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan A.","family":"Menges","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Abraham-Miranda","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Savid-Frontera","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sawyer","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasu D.","family":"Sorathia","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8037-9784","authenticated-orcid":false,"given":"Luis A.","family":"Cuadrado Delgado","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore A.","family":"Corallo","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3928-4018","authenticated-orcid":false,"given":"Julia C.","family":"Llanos","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Merritt","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"de Avila","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[{"name":"4Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[{"name":"5Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Blue","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1771","authenticated-orcid":false,"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[{"name":"5Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-8672","authenticated-orcid":false,"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[{"name":"4Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-6244","authenticated-orcid":false,"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"5Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-686X","authenticated-orcid":false,"given":"Jennifer M.","family":"Binning","sequence":"additional","affiliation":[{"name":"6Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald M.","family":"Atkins","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Song","sequence":"additional","affiliation":[{"name":"7Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026091007215618500_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"2026091007215618500_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026091007215618500_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"issue":"10297","key":"2026091007215618500_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"2026091007215618500_bib5","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026091007215618500_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"2026091007215618500_bib7","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026091007215618500_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026091007215618500_bib9","doi-asserted-by":"crossref","first-page":"e002555","DOI":"10.1136\/jitc-2021-002555","article-title":"Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies","volume":"9","author":"Daniela","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"issue":"8","key":"2026091007215618500_bib10","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1016\/j.ymthe.2025.04.019","article-title":"Enhanced CAR-T function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma","volume":"33","author":"Freeman","year":"2025","journal-title":"Mol Ther"},{"issue":"19","key":"2026091007215618500_bib11","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl","key":"2026091007215618500_bib12","first-page":"759","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T-cell therapy","volume":"6","author":"Julie Rytlewski","year":"2022","journal-title":""},{"issue":"6","key":"2026091007215618500_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"issue":"13","key":"2026091007215618500_bib14","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2026091007215618500_bib15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"2026091007215618500_bib16","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","article-title":"A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-Seq","volume":"28","author":"Boroughs","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"2026091007215618500_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"issue":"15","key":"2026091007215618500_bib18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026091007215618500_bib19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ccell.2023.08.015","article-title":"A single-cell atlas of CD19 chimeric antigen receptor T cells","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"2026091007215618500_bib20","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026091007215618500_bib21","doi-asserted-by":"crossref","first-page":"e20231348","DOI":"10.1084\/jem.20231348","article-title":"NF-\u03baB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer","volume":"221","author":"Lalle","year":"2024","journal-title":"J Exp Med"},{"issue":"1","key":"2026091007215618500_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2026091007215618500_bib23","doi-asserted-by":"crossref","first-page":"e011807","DOI":"10.1136\/jitc-2025-011807","article-title":"Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing","volume":"13","author":"Yu","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2026091007215618500_bib24","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1016\/j.bict.2026.100036","article-title":"Preapheresis clinical patient profiles predict patient\u2019s manufacturing fitness and efficacy with idecabtagene vicleucel","volume":"2","author":"Rytlewski","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"issue":"6","key":"2026091007215618500_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"2026091007215618500_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/bloodadvances.2024015285","article-title":"Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma","volume":"9","author":"Waldschmidt","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026091007215618500_bib27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"2026091007215618500_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2026091007215618500_bib29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2026091007215618500_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1409\/2588126\/blood_bld-2025-031843-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1409\/2588126\/blood_bld-2025-031843-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:22:23Z","timestamp":1789039343000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/11\/1409\/569094\/Product-intrinsic-NF-B-driven-transcriptional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031843","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,10]]},"published":{"date-parts":[[2026,9,10]]}}}